MPLN News


MPLN expands oncology offering with Next Generation Sequencing based mutation panels for evaluation

Posted on May 18 2017 by J Seabrook

Myeloproliferative neoplasms (MPNs) are characterized by excess accumulation of one or more myeloid cell lineages and a tendency to transform to acute leukemia.  Clinical data and practice guidelines have evolved at a rapid pace for this heterogeneous…
Read more


PD-L1_Hi_power_web.png

MPLN offers VENTANA SP263 PDL-1 by IHC

Posted on May 02 2017 by J Seabrook

MPLN offers SP263 immunohistochemical testing for the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded tissue. PD-L1 expression level utilizing this clone has been associated with response to durvalumab (IMFINZI, AstraZeneca UK…
Read more


Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic

Posted on March 06 2017 by J Seabrook

Results of the study with the blood test Epi proColon® is now published in the journal of “Cancer Treatment and Research Communications”. Read more


Twitter_graphic.JPG

MPLN and Geneuity Twitter News Feed

Posted on February 21 2017 by J Seabrook

You can view MPLN's Twitter Feed by clicking here @molpathnet

Molecular Pathology Laboratory Network, custom services for #oncologists #pathologists;
experience in #flowcytometry…
Read more


Laboratory Developed Tests Roadmap and IVD Vendors

Posted on December 13 2016 by J Seabrook

MPLN follows a development process for laboratory developed tests. A phased approach is useful for organizing and assessing the performance of an assay. 

Read more


1 2 3 4 5 6 7 8